{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mentzer AJ"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","Wellcome Trust","Academy of Medical Sciences"],"pagination":["147-157"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9873562"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(1)"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with vaccine efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 vaccine efficacy trials in the United Kingdom, we found that inter-individual variation in normalized antibody responses against SARS-CoV-2 spike and its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association with major histocompatibility complex (MHC) class II alleles. The most statistically significant association with higher levels of anti-RBD antibody was HLA-DQB1*06 (P = 3.2 × 10<sup>-9</sup>), which we replicated in 1,677 additional vaccinees. Individuals carrying HLA-DQB1*06 alleles were less likely to expe"],"journal":["Nature medicine"],"pubmed_title":["Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection."],"pmcid":["PMC9873562"],"funding_grant_id":["203141/Z/16/Z","CL-2018-13-007","204969/Z/16/Z","211153/Z/18/Z","SGL024\\1096","MC_UU_00004/04","NIHR201409"],"pubmed_authors":["Ferreira DM","Hanumunthadu B","Bull MB","Minassian A","Pollard AJ","Fowler J","Marchevsky N","Cifuentes L","Clutterbuck EA","Godfrey L","Lazarus R","O'Connor D","Adlou S","Hill H","Emary KRW","Karp-Tatham E","Li G","Oxford COVID Vaccine Trial Genetics Study Team Group","Shaw RH","Lambe T","Turnbull I","Finn A","Felle S","Chong AY","Kwok J","Green CA","Heath P","Ramasamy MN","Libri V","Bibi S","Flaxman AL","Sanders K","Stuart A","Feng S","Alamad B","Pollock K","Faust SN","Sutherland RK","Thomson EC","Williams CJA","Beveridge A","Chelysheva I","Lillie PJ","Liu X","Snape MD","Darton T","Malinauskas T","Duncan CJA","Khozoee B","Mentzer AJ","Dinesh T","Collins AM","Toshner M","Knight JC","Provtsgaard-Morys S","Voysey M","Makinson R","McGregor AC","Hart T","Smith A","Edwards NJ","Turner DPJ","Goodman AL","Payne RO","Smith CC","Angus B","Cicconi P","Cavey A","Anslow R","Demissie T"],"additional_accession":[]},"is_claimable":false,"name":"Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with vaccine efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 vaccine efficacy trials in the United Kingdom, we found that inter-individual variation in normalized antibody responses against SARS-CoV-2 spike and its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association with major histocompatibility complex (MHC) class II alleles. The most statistically significant association with higher levels of anti-RBD antibody was HLA-DQB1*06 (P = 3.2 × 10<sup>-9</sup>), which we replicated in 1,677 additional vaccinees. Individuals carrying HLA-DQB1*06 alleles were less likely to expe","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-10T06:54:29.385Z","creation":"2025-04-07T03:20:15.97Z"},"accession":"S-EPMC9873562","cross_references":{"pubmed":["36228659"],"doi":["10.1038/s41591-022-02078-6"]}}